Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Trial details
- Registry ID
- NCT07211958
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationNCT07211958 | Syndax Pharmaceuticals | Phase 3 | Recruiting | 2029-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |